Prostaglandin E2 and nitric oxide mediate the acute inflammatory (erythemal) response to topical 5-aminolaevulinic acid photodynamic therapy in human skin

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 645-652

  Brooke, R C C ^a   Sidhu, M ^a   Sinha, A ^a   Watson, R E B ^a   Friedmann, P S ^b   Clough, G F ^b   Rhodes, Lesley E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; GLYCERYL TRINITRATE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE; PHOTOSENSITIZING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; ERYTHEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; IONTOPHORESIS; IRRADIATION; MALE; NORMAL HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RED LIGHT; SKIN; AGED; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG ERUPTION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AMINOLEVULINIC ACID; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG ERUPTIONS; ENZYME INHIBITORS; ERYTHEMA; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; YOUNG ADULT;

EID: 84883348770     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12562     Document Type: Article

References (47)

1. Morton CA, Brown SB, Collins S, et al,. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146: 552-67.
2. Morton CA, McKenna KE, Rhodes LE,. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-66.
3. Ortel B, Shea CR, Calzavara-Pinton P,. Molecular mechanisms of photodynamic therapy. Front Biosci 2009; 14: 4157-72.
4. Reeves KJ, Reed MW, Brown NJ,. The role of nitric oxide in the treatment of tumours with aminolaevulinic acid-induced photodynamic therapy. J Photochem Photobiol, B 2010; 101: 224-32.
5. Nakaseko H, Kobayashi M, Akita Y, et al,. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratosis. Br J Dermatol 2003; 148: 122-7.
6. Firczuk M, Nowis D, Goła̧b J,. PDT-induced inflammatory and host responses. Photochem Photobiol Sci 2011; 10: 653-63.
7. Evangelou G, Farrar MD, White RD, et al,. Topical ALA-PDT produces an inflammatory infiltrate but reduces Langerhans cells in healthy human skin in vivo. Br J Dermatol 2011; 165: 513-19.
8. Schacht V, Szeimies RM, Abels C,. Photodynamic therapy with 5-aminolevulinic acid induces distinct microcirculatory effects following systemic or topical application. Photochem Photobiol Sci 2006; 5: 452-8.
9. Brooke RC, Sinha A, Sidhu MK, et al,. Histamine is released following aminolevulinic acid-photodynamic therapy of human skin and mediates an aminolevulinic acid dose-related immediate inflammatory response. J Invest Dermatol 2006; 126: 2296-301.
10. Rhodes LE, Tsoukas MM, Anderson RR, Kollias N,. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J Invest Dermatol 1997; 108: 87-91.
11. Clark CR, Dawe S, Moseley H, et al,. The characteristics of erythema induced by topical 5-aminolaevulinic acid photodynamic therapy. Photodermatol Photoimmunol Photomed 2004; 20: 105-7.
12. Weller R,. Nitric oxide: a key mediator in cutaneous physiology. Clin Exp Dermatol 2006; 28: 511-14.
13. Wang MT, Honn KV, Nie D,. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007; 26: 525-34.
14. 2 from cells by photodynamic treatment in vitro. Cancer Res 1989; 49: 6896-900.
15. 2 induction reduces haematoporphyrin-derivative-induced cytotoxicity of T24 human bladder transitional carcinoma cells in vitro. Biochem J 1993; 292: 237-40.
16. Ali S, Olivo M,. Nitric oxide mediated photo-induced cell death in human malignant cells. Int J Oncol 2003; 22: 751-6.
17. Bircher AE, de Boer M, Agner T, et al,. Guidelines for measurement of cutaneous blood flow by laser Doppler flowmetry. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1994; 30: 65-72.
18. 2 in combination. J Invest Dermatol 2001; 117: 880-5.
19. Boutsiouki P, Georgiou S, Clough GF,. Recovery of nitric oxide from acetylcholine-mediated vasodilatation in human skin in vivo. Microcirculation 2004; 11: 249-59.
20. Clough GF, Bennett AR, Church MK,. Measurement of nitric oxide concentration in human skin in vivo using dermal microdialysis. Exp Physiol 1998; 83: 431-4.
21. Lesar A, Ferguson J, Moseley H,. An investigation of the fluorescence induced by topical application of 5-aminolaevulinic acid and methyl aminolaevulinate at different body sites on normal human skin. Photodiagnosis Photodyn Ther 2011; 8: 97-103.
22. al-Laith M, Matthews EK, Cui ZJ,. Photodynamic drug action on isolated rat pancreatic acini. Mobilization of arachidonic acid and prostaglandin production. Biochem Pharmacol 1993; 46: 567-73.
23. Coutier S, Bezdetnaya L, Marchal S, et al,. Foscan (mTHPC) photosensitized macrophage activation: enhancement of phagocytosis, nitric oxide release and tumour necrosis factor-alpha-mediated cytolytic activity. Br J Cancer 1999; 81: 37-42.
24. Gupta S, Ahmad N, Mukhtar H,. Involvement of nitric oxide during phthalocyanine (Pc4) photodynamic therapy-mediated apoptosis. Cancer Res 1998; 58: 1785-8.
25. Fingar VH, Wieman TJ, Doak KW,. Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res 1990; 50: 2599-603.
26. Schulten R, Novak B, Schmitz B, Lübbert H,. Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 969-79.
27. de Bruijn HS, Meijers C, van der Ploeg-van den Heuvel A, et al,. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate. J Photochem Photobiol, B 2008; 92: 91-7.
28. Gerscher S, Connelly JP, Griffiths J, et al,. Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo. Photochem Photobiol 2000; 72: 569-74.
29. Sakamoto FH, Tannous Z, Doukas AG, et al,. Porphyrin distribution after topical aminolevulinic acid in a novel porcine model of sebaceous skin. Lasers Surg Med 2009; 41: 154-60.
30. Ryter SW, Gomer CJ,. Nuclear factor kappa B binding activity in mouse L1210 cells following photofrin II-mediated photosensitization. Photochem Photobiol 1993; 58: 753-6.
31. Volanti C, Hendrickx N, Van Lint J, et al,. Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy. Oncogene 2005; 24: 2981-91.
32. Agarwal ML, Larkin HE, Zaidi SI, et al,. Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Cancer Res 1993; 53: 5897-902.
33. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB,. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004; 1704: 59-86.
34. Imokawa G, Tejima T,. A possible role of prostaglandins in PUVA-induced inflammation: implication by organ cultured skin. J Invest Dermatol 1989; 92: 296-300.
35. Warren JB,. Nitric oxide and human skin blood flow responses to acetylcholine and ultraviolet light. FASEB J 1994; 8: 247-51.
36. Ibbotson SH,. Adverse effects of topical photodynamic therapy. Photodermatol Photoimmunol Photomed 2011; 27: 116-30.
37. Cecic I, Korbelik M,. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 2002; 183: 43-51.
38. de Bruijn HS, Sluiter W, van der Ploeg-van den Heuvel A, et al,. Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy. Photodermatol Photoimmunol Photomed 2006; 22: 238-46.
39. Ferrario A, Gomer CJ,. Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor. Methods Mol Biol 2010; 635: 121-32.
40. Makowski M, Grzela T, Niderla J, et al,. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res 2003; 9: 5417-22.
41. Ferrario A, Fisher AM, Rucker N, Gomer CJ,. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005; 65: 9473-8.
42. Bhowmick R, Girotti AW,. Cytoprotective induction of nitric oxide synthase in a cellular model of 5-aminolevulinic acid-based photodynamic therapy. Free Radic Biol Med 2010; 48: 1296-301.
43. Jadeski LC, Hum KO, Chakraborty C, Lala PK,. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000; 86: 30-9.
44. Bhowmick R, Girotti AW,. Rapid upregulation of cytoprotective nitric oxide in breast tumor cells subjected to a photodynamic therapy-like oxidative challenge. Photochem Photobiol 2011; 87: 378-86.
45. Yamamoto F, Ohgari Y, Yamaki N, et al,. The role of nitric oxide in delta-aminolevulinic acid (ALA)-induced photosensitivity of cancerous cells. Biochem Biophys Res Commun 2007; 353: 541-6.
46. Korbelik M, Parkins CS, Shibuya H, et al,. Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer 2000; 82: 1835-43.
47. Henderson BW, Sitnik-Busch TM, Vaughan LA,. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent. Photochem Photobiol 1999; 70: 64-71.